Constipation Clinical Trial
Official title:
Effect of Kiwifruit on Gastrointestinal Fluid Distribution and Transit in Healthy Volunteers
Constipation is a widespread and common problem in which a person finds it difficult and/or
painful to open their bowels. The current treatment is the use of medications called
laxatives. Kiwifruit is a widely available food that has been shown to possess some laxative
properties. The cause of this is unknown. Non-invasive medical imaging techniques such as
Magnetic Resonance Imaging now allow taking pictures of the gut and its contents. The
Nottingham GI MRI research group specialises in these techniques and in this study use such
images to assess the changes induced in the gut contents by kiwifruit to improve
understanding of how it helps patients with constipation.
The volunteers will be asked to undergo 2 studies in which they take either kiwifruit or
placebo (sugary drink) two times a day for 2 days and then spend a study day where will they
will be fed some more kiwifruit/placebo and some normal food and image their gut at
intervals. Participants will be asked to complete a stool diary to determine if they
experience a laxative effect.
1. Background. Chronic constipation affects approximately 17% of the population worldwide
and remains an important unmet need since patients are currently often dissatisfied with
treatment Current treatments which stimulate propulsive colonic motility or osmotic
laxatives are successful in increasing stool frequency but are often associated with
bloating, cramps and abdominal discomfort. Furthermore, such powerful treatments taken
intermittently often create abnormal colonic contents and may result in alternation
between diarrhoea and no stools. Many patients would benefit from a less powerful
treatment which could be taken daily. Kiwifruit offer such an alternative and have been
shown to increase stool volume and frequency. The mode of action however is unclear.
Kiwi is 3% fibre (approximately 1/3 insoluble) and contains around 3% nonstarch
polysaccharide including pectins, hemicellulose and cellulose, with high water holding
capacity 1.5 times that of ispaghula, a commonly used laxative. Using recently developed
and validated novel non-invasive MRI techniques, the University can assess transit and
fluid distribution in the small intestine [4]. The University has also developed methods
to assess colonic fluid, volumes and motility.
2. Aims. To assess the effect of kiwifruit on gastrointestinal fluid distribution.
3. Experimental protocol and methods. A randomised, placebo controlled, 2-way cross-over
study in N=15 healthy volunteers assessing the response (versus baseline values) of 2
kiwifruit b.d vs placebo (28 gm maltodextrin drink providing 120kcal equal to that of 2
kiwifruit) daily. After a screening visit to confirm eligibility, study subjects will be
randomised as to the test product schedule. Subjects will complete a daily stool diary
documenting stool frequency and consistency using the Bristol Stool Form Scale. They
will consume the test product allocated starting on Day 4. At 9 am of the morning of Day
5 they will ingest 5 MRI transit markers as described below and note the time of
ingestion. The markers will be imaged at 24 hours (baseline scan of Day 6). On the main
study day, the subjects will arrive fasted overnight and undergo fasting scans before
consuming that day's allocated test product with 250ml of water. After 30 minutes
considered to be Time =0 they will consume a standard rice pudding meal as used in
previous studies. They will then undergo serial scanning hourly for 7 hours taking the
second dose of test product plus 250ml water at Time 180 minutes. The third dose is
taken at 320 minutes followed at 380 minutes by a second, larger test meal consisting of
400 g microwaveable macaroni cheese ready meal (Sainsbury), 100 g cheesecake slice
(Sainsbury), and 250 mL bottled still water. The second test meal provides approx. 1000
kcal. The final scan will at time 420 minutes to assess the effect of ileal emptying on
gastrointestinal fluid distribution. They will then be allowed home. There will be 2
weeks between studies to ensure return to baseline. At the end of the study a further 3
participants will be scanned in exactly the same protocol however at a lower dose of
kiwifruit (2 fruit once daily) to determine if the effect is still visible.
4. Measurable end points/statistical power of the study. Primary endpoint: Effect of
Kiwifruit on Ascending colon T1 area under curve from time 0-420.
Secondary endpoints: Effect of Kiwifruit on the following measures both fasting and
postprandial AUC 0-420 minutes: 1) small bowel water content 2) ascending (AC), transverse
(TC) and descending (DC) colonic volumes. 3) Transit of markers through gut as assessed by
the weighted position score at 24 h (WAPS24) 4) Colonic motility 5) Gastric emptying of test
meal 6) T1 of AC and DC. Pilot data with a standard laxative dose of ispaghula 7g t.d.s.
showed a change of T1 AUC 0-360 of mean (SD) 88 (55) sec.min . Using this data n=15 healthy
volunteers will give us >90% power to detect such a difference.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 |